1
|
Pawelec KM, Hix JML, Troia A, MacRenaris KW, Kiupel M, Shapiro EM. In vivo micro-computed tomography evaluation of radiopaque, polymeric device degradation in normal and inflammatory environments. Acta Biomater 2024; 181:222-234. [PMID: 38648912 PMCID: PMC11144086 DOI: 10.1016/j.actbio.2024.04.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2024] [Revised: 03/26/2024] [Accepted: 04/18/2024] [Indexed: 04/25/2024]
Abstract
Polymeric biomedical implants are an important clinical tool, but degradation remains difficult to determine post-implantation. Computed tomography (CT) could be a powerful tool for device monitoring, but polymers require incorporation of radiopaque contrast agents to be distinguishable from tissue. In addition, immune response to radiopaque devices must be characterized as it modulates device function. Radiopaque devices and films were produced by incorporating 0-20 wt% TaOx nanoparticles into polymers: polycaprolactone (PCL) and poly(lactide-co-glycolide) (PLGA). In vitro inflammatory responses of mouse bone marrow-derived macrophages to polymer matrix incorporating TaOx nanoparticles was determined by monitoring cytokine secretion. Nanoparticle addition stimulated a slight inflammatory reaction, increasing TNFα secretion, mediated by changes in polymer matrix properties. Subsequently, devices (PLGA 50:50 + 20 wt% TaOx) were implanted subcutaneously in a mouse model of chronic inflammation, that featured a sustained increase in inflammatory response local to the implant site over 12 weeks. No changes to device degradation rates or foreign body response were noted between a normal and chronically stimulated inflammatory environment. Serial CT device monitoring post-implantation provided a detailed timeline of device collapse, with no rapid, spontaneous release of nanoparticles that occluded matrix visualization. Importantly, repeat CT sessions did not ablate the immune system or alter degradation kinetics. Thus, polymer devices incorporating radiopaque nanoparticles can be used for in situ monitoring and be readily combined with other medical imaging techniques, for a dynamic view biomaterial and tissue interactions. STATEMENT OF SIGNIFICANCE: A growing number of implantable devices are in use in the clinic, exposing patients to inherent risks of implant movement, collapse, and infection. The ability to monitor implanted devices would enable faster diagnosis of failure and open the door for personalized rehabilitation therapies - both of which could vastly improve patient outcomes. Unfortunately, polymeric materials which make up most biomedical devices are not radiologically distinguishable from tissue post-implantation. The introduction of radiopaque nanoparticles into polymers allows for serial monitoring via computed tomography, without affecting device degradation. Here we demonstrate for the first time that nanoparticles do not undergo burst release from devices post-implantation and that inflammatory responses - a key determinant of device function in vivo - are also unaffected by nanoparticle addition.
Collapse
Affiliation(s)
- Kendell M Pawelec
- Department of Radiology, Michigan State University, East Lansing, MI 48824, USA; Institute for Quantitative Health Sciences and Engineering, Michigan State University, East Lansing, MI 48824, USA.
| | - Jeremy M L Hix
- Department of Radiology, Michigan State University, East Lansing, MI 48824, USA; Institute for Quantitative Health Sciences and Engineering, Michigan State University, East Lansing, MI 48824, USA
| | - Arianna Troia
- Department of Radiology, Michigan State University, East Lansing, MI 48824, USA
| | - Keith W MacRenaris
- Quantitative Bio Element Analysis and Mapping (QBEAM) Center, Michigan State University, East Lansing, MI 48824, USA
| | - Matti Kiupel
- Department of Pathobiology and Diagnostic Investigation, Michigan State University, East Lansing, MI 48824, USA
| | - Erik M Shapiro
- Department of Radiology, Michigan State University, East Lansing, MI 48824, USA; Institute for Quantitative Health Sciences and Engineering, Michigan State University, East Lansing, MI 48824, USA; Department of Physiology, Michigan State University, East Lansing, MI 48824, USA; Department of Chemical Engineering and Material Science, Michigan State University, East Lansing, MI 48824, USA; Department of Biomedical Engineering, Michigan State University, East Lansing, MI 48824, USA.
| |
Collapse
|
2
|
Pawelec KM, Schoborg TA, Shapiro EM. Computed tomography technologies to measure key structural features of polymeric biomedical implants from bench to bedside. J Biomed Mater Res A 2024. [PMID: 38728118 DOI: 10.1002/jbm.a.37735] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2024] [Revised: 04/11/2024] [Accepted: 04/30/2024] [Indexed: 05/12/2024]
Abstract
Implanted polymeric devices, designed to encourage tissue regeneration, require porosity. However, characterizing porosity, which affects many functional device properties, is non-trivial. Computed tomography (CT) is a quick, versatile, and non-destructive way to gain 3D structural information, yet various CT technologies, such as benchtop, preclinical and clinical systems, all have different capabilities. As system capabilities determine the structural information that can be obtained, seamless monitoring of key device features through all stages of clinical translation must be engineered intentionally. Therefore, in this study we tested feasibility of obtaining structural information in pre-clinical systems and high-resolution micro-CT (μCT) under physiological conditions. To overcome the low CT contrast of polymers in hydrated environments, radiopaque nanoparticle contrast agent was incorporated into porous devices. The size of resolved features in porous structures is highly dependent on the resolution (voxel size) of the scan. As the voxel size of the CT scan increased (lower resolution) from 5 to 50 μm, the measured pore size was overestimated, and percentage porosity was underestimated by nearly 50%. With the homogeneous introduction of nanoparticles, changes to device structure could be quantified in the hydrated state, including at high-resolution. Biopolymers had significant structural changes post-hydration, including a mean increase of 130% in pore wall thickness that could potentially impact biological response. By incorporating imaging capabilities into polymeric devices, CT can be a facile way to monitor devices from initial design stages through to clinical translation.
Collapse
Affiliation(s)
- Kendell M Pawelec
- Department of Radiology, Michigan State University, East Lansing, Michigan, USA
- Institute for Quantitative Health Sciences and Engineering, Michigan State University, East Lansing, Michigan, USA
| | - Todd A Schoborg
- Department of Molecular Biology, University of Wyoming, Laramie, Wyoming, USA
| | - Erik M Shapiro
- Department of Radiology, Michigan State University, East Lansing, Michigan, USA
- Institute for Quantitative Health Sciences and Engineering, Michigan State University, East Lansing, Michigan, USA
- Department of Physiology, Michigan State University, East Lansing, Michigan, USA
- Department of Chemical Engineering and Material Science, Michigan State University, East Lansing, Michigan, USA
- Department of Biomedical Engineering, Michigan State University, East Lansing, Michigan, USA
| |
Collapse
|
3
|
Douek PC, Boccalini S, Oei EHG, Cormode DP, Pourmorteza A, Boussel L, Si-Mohamed SA, Budde RPJ. Clinical Applications of Photon-counting CT: A Review of Pioneer Studies and a Glimpse into the Future. Radiology 2023; 309:e222432. [PMID: 37787672 PMCID: PMC10623209 DOI: 10.1148/radiol.222432] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2022] [Revised: 03/24/2023] [Accepted: 04/11/2023] [Indexed: 10/04/2023]
Abstract
CT systems equipped with photon-counting detectors (PCDs), referred to as photon-counting CT (PCCT), are beginning to change imaging in several subspecialties, such as cardiac, vascular, thoracic, and musculoskeletal radiology. Evidence has been building in the literature underpinning the many advantages of PCCT for different clinical applications. These benefits derive from the distinct features of PCDs, which are made of semiconductor materials capable of converting photons directly into electric signal. PCCT advancements include, among the most important, improved spatial resolution, noise reduction, and spectral properties. PCCT spatial resolution on the order of 0.25 mm allows for the improved visualization of small structures (eg, small vessels, arterial walls, distal bronchi, and bone trabeculations) and their pathologies, as well as the identification of previously undetectable anomalies. In addition, blooming artifacts from calcifications, stents, and other dense structures are reduced. The benefits of the spectral capabilities of PCCT are broad and include reducing radiation and contrast material dose for patients. In addition, multiple types of information can be extracted from a single data set (ie, multiparametric imaging), including quantitative data often regarded as surrogates of functional information (eg, lung perfusion). PCCT also allows for a novel type of CT imaging, K-edge imaging. This technique, combined with new contrast materials specifically designed for this modality, opens the door to new applications for imaging in the future.
Collapse
Affiliation(s)
| | | | - Edwin H. G. Oei
- From the University of Lyon, INSA-Lyon, Claude Bernard Lyon 1
University, UJM-Saint Etienne, CNRS, Inserm, Villeurbanne, France (P.C.D., L.B.,
S.A.S.M.); Department of Cardiovascular and Thoracic Radiology, Louis Pradel
Hospital, Hospices Civils de Lyon, 59 Boulevard Pinel, 69500 Bron, France
(P.C.D., S.B., L.B., S.A.S.M.); Claude Bernard Lyon 1 University, Villeurbanne,
France (S.B.); Department of Radiology and Nuclear Medicine, Erasmus Medical
Center, Rotterdam, the Netherlands (E.H.G.O., R.P.J.B.); Department of
Radiology, University of Pennsylvania, Philadelphia, Pa (D.P.C.); Department of
Radiology and Imaging Sciences, Emory University, Atlanta, Ga (A.P.); Department
of Biomedical Engineering, Georgia Institute of Technology, Atlanta, Ga (A.P.);
and Winship Cancer Institute, Atlanta, Ga (A.P.)
| | - David P. Cormode
- From the University of Lyon, INSA-Lyon, Claude Bernard Lyon 1
University, UJM-Saint Etienne, CNRS, Inserm, Villeurbanne, France (P.C.D., L.B.,
S.A.S.M.); Department of Cardiovascular and Thoracic Radiology, Louis Pradel
Hospital, Hospices Civils de Lyon, 59 Boulevard Pinel, 69500 Bron, France
(P.C.D., S.B., L.B., S.A.S.M.); Claude Bernard Lyon 1 University, Villeurbanne,
France (S.B.); Department of Radiology and Nuclear Medicine, Erasmus Medical
Center, Rotterdam, the Netherlands (E.H.G.O., R.P.J.B.); Department of
Radiology, University of Pennsylvania, Philadelphia, Pa (D.P.C.); Department of
Radiology and Imaging Sciences, Emory University, Atlanta, Ga (A.P.); Department
of Biomedical Engineering, Georgia Institute of Technology, Atlanta, Ga (A.P.);
and Winship Cancer Institute, Atlanta, Ga (A.P.)
| | - Amir Pourmorteza
- From the University of Lyon, INSA-Lyon, Claude Bernard Lyon 1
University, UJM-Saint Etienne, CNRS, Inserm, Villeurbanne, France (P.C.D., L.B.,
S.A.S.M.); Department of Cardiovascular and Thoracic Radiology, Louis Pradel
Hospital, Hospices Civils de Lyon, 59 Boulevard Pinel, 69500 Bron, France
(P.C.D., S.B., L.B., S.A.S.M.); Claude Bernard Lyon 1 University, Villeurbanne,
France (S.B.); Department of Radiology and Nuclear Medicine, Erasmus Medical
Center, Rotterdam, the Netherlands (E.H.G.O., R.P.J.B.); Department of
Radiology, University of Pennsylvania, Philadelphia, Pa (D.P.C.); Department of
Radiology and Imaging Sciences, Emory University, Atlanta, Ga (A.P.); Department
of Biomedical Engineering, Georgia Institute of Technology, Atlanta, Ga (A.P.);
and Winship Cancer Institute, Atlanta, Ga (A.P.)
| | - Loic Boussel
- From the University of Lyon, INSA-Lyon, Claude Bernard Lyon 1
University, UJM-Saint Etienne, CNRS, Inserm, Villeurbanne, France (P.C.D., L.B.,
S.A.S.M.); Department of Cardiovascular and Thoracic Radiology, Louis Pradel
Hospital, Hospices Civils de Lyon, 59 Boulevard Pinel, 69500 Bron, France
(P.C.D., S.B., L.B., S.A.S.M.); Claude Bernard Lyon 1 University, Villeurbanne,
France (S.B.); Department of Radiology and Nuclear Medicine, Erasmus Medical
Center, Rotterdam, the Netherlands (E.H.G.O., R.P.J.B.); Department of
Radiology, University of Pennsylvania, Philadelphia, Pa (D.P.C.); Department of
Radiology and Imaging Sciences, Emory University, Atlanta, Ga (A.P.); Department
of Biomedical Engineering, Georgia Institute of Technology, Atlanta, Ga (A.P.);
and Winship Cancer Institute, Atlanta, Ga (A.P.)
| | - Salim A. Si-Mohamed
- From the University of Lyon, INSA-Lyon, Claude Bernard Lyon 1
University, UJM-Saint Etienne, CNRS, Inserm, Villeurbanne, France (P.C.D., L.B.,
S.A.S.M.); Department of Cardiovascular and Thoracic Radiology, Louis Pradel
Hospital, Hospices Civils de Lyon, 59 Boulevard Pinel, 69500 Bron, France
(P.C.D., S.B., L.B., S.A.S.M.); Claude Bernard Lyon 1 University, Villeurbanne,
France (S.B.); Department of Radiology and Nuclear Medicine, Erasmus Medical
Center, Rotterdam, the Netherlands (E.H.G.O., R.P.J.B.); Department of
Radiology, University of Pennsylvania, Philadelphia, Pa (D.P.C.); Department of
Radiology and Imaging Sciences, Emory University, Atlanta, Ga (A.P.); Department
of Biomedical Engineering, Georgia Institute of Technology, Atlanta, Ga (A.P.);
and Winship Cancer Institute, Atlanta, Ga (A.P.)
| | - Ricardo P. J. Budde
- From the University of Lyon, INSA-Lyon, Claude Bernard Lyon 1
University, UJM-Saint Etienne, CNRS, Inserm, Villeurbanne, France (P.C.D., L.B.,
S.A.S.M.); Department of Cardiovascular and Thoracic Radiology, Louis Pradel
Hospital, Hospices Civils de Lyon, 59 Boulevard Pinel, 69500 Bron, France
(P.C.D., S.B., L.B., S.A.S.M.); Claude Bernard Lyon 1 University, Villeurbanne,
France (S.B.); Department of Radiology and Nuclear Medicine, Erasmus Medical
Center, Rotterdam, the Netherlands (E.H.G.O., R.P.J.B.); Department of
Radiology, University of Pennsylvania, Philadelphia, Pa (D.P.C.); Department of
Radiology and Imaging Sciences, Emory University, Atlanta, Ga (A.P.); Department
of Biomedical Engineering, Georgia Institute of Technology, Atlanta, Ga (A.P.);
and Winship Cancer Institute, Atlanta, Ga (A.P.)
| |
Collapse
|
4
|
Schwartz FR, Samei E, Marin D. Exploiting the Potential of Photon-Counting CT in Abdominal Imaging. Invest Radiol 2023; 58:488-498. [PMID: 36728045 DOI: 10.1097/rli.0000000000000949] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
ABSTRACT Photon-counting computed tomography (PCCT) imaging uses a new detector technology to provide added information beyond what can already be obtained with current CT and MR technologies. This review provides an overview of PCCT of the abdomen and focuses specifically on applications that benefit the most from this new imaging technique. We describe the requirements for a successful abdominal PCCT acquisition and the challenges for clinical translation. The review highlights work done within the last year with an emphasis on new protocols that have been tested in clinical practice. Applications of PCCT include imaging of cystic lesions, sources of bleeding, and cancers. Photon-counting CT is positioned to move beyond detection of disease to better quantitative staging of disease and measurement of treatment response.
Collapse
Affiliation(s)
| | - Ehsan Samei
- Quantitative Imaging and Analysis Lab, Duke University Health System, Durham, NC
| | | |
Collapse
|
5
|
Si-Mohamed SA, Boccalini S, Villien M, Yagil Y, Erhard K, Boussel L, Douek PC. First Experience With a Whole-Body Spectral Photon-Counting CT Clinical Prototype. Invest Radiol 2023; 58:459-471. [PMID: 36822663 PMCID: PMC10259214 DOI: 10.1097/rli.0000000000000965] [Citation(s) in RCA: 11] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2022] [Accepted: 01/20/2023] [Indexed: 02/25/2023]
Abstract
ABSTRACT Spectral photon-counting computed tomography (SPCCT) technology holds great promise for becoming the next generation of computed tomography (CT) systems. Its technical characteristics have many advantages over conventional CT imaging. For example, SPCCT provides better spatial resolution, greater dose efficiency for ultra-low-dose and low-dose protocols, and tissue contrast superior to that of conventional CT. In addition, SPCCT takes advantage of several known approaches in the field of spectral CT imaging, such as virtual monochromatic imaging and material decomposition imaging. In addition, SPCCT takes advantage of a new approach in this field, known as K-edge imaging, which allows specific and quantitative imaging of a heavy atom-based contrast agent. Hence, the high potential of SPCCT systems supports their ongoing investigation in clinical research settings. In this review, we propose an overview of our clinical research experience of a whole-body SPCCT clinical prototype, to give an insight into the potential benefits for clinical human imaging on image quality, diagnostic confidence, and new approaches in spectral CT imaging.
Collapse
Affiliation(s)
- Salim A. Si-Mohamed
- From the University Lyon, INSA-Lyon, University Claude Bernard Lyon 1, UJM-Saint Etienne, CNRS, Inserm, Villeurbanne, France
- Department of Radiology, Louis Pradel Hospital, Hospices Civils de Lyon, Bron, France
| | - Sara Boccalini
- From the University Lyon, INSA-Lyon, University Claude Bernard Lyon 1, UJM-Saint Etienne, CNRS, Inserm, Villeurbanne, France
- Department of Radiology, Louis Pradel Hospital, Hospices Civils de Lyon, Bron, France
| | | | | | | | - Loic Boussel
- From the University Lyon, INSA-Lyon, University Claude Bernard Lyon 1, UJM-Saint Etienne, CNRS, Inserm, Villeurbanne, France
- Department of Radiology, Louis Pradel Hospital, Hospices Civils de Lyon, Bron, France
| | - Philippe C. Douek
- From the University Lyon, INSA-Lyon, University Claude Bernard Lyon 1, UJM-Saint Etienne, CNRS, Inserm, Villeurbanne, France
- Department of Radiology, Louis Pradel Hospital, Hospices Civils de Lyon, Bron, France
| |
Collapse
|
6
|
Cademartiri F, Meloni A, Pistoia L, Degiorgi G, Clemente A, De Gori C, Positano V, Celi S, Berti S, Emdin M, Panetta D, Menichetti L, Punzo B, Cavaliere C, Bossone E, Saba L, Cau R, Grutta LL, Maffei E. Dual Source Photon-Counting Computed Tomography-Part II: Clinical Overview of Neurovascular Applications. J Clin Med 2023; 12:jcm12113626. [PMID: 37297821 DOI: 10.3390/jcm12113626] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2023] [Revised: 05/15/2023] [Accepted: 05/18/2023] [Indexed: 06/12/2023] Open
Abstract
Photon-counting detector (PCD) is a novel computed tomography detector technology (photon-counting computed tomography-PCCT) that presents many advantages in the neurovascular field, such as increased spatial resolution, reduced radiation exposure, and optimization of the use of contrast agents and material decomposition. In this overview of the existing literature on PCCT, we describe the physical principles, the advantages and the disadvantages of conventional energy integrating detectors and PCDs, and finally, we discuss the applications of the PCD, focusing specifically on its implementation in the neurovascular field.
Collapse
Affiliation(s)
| | - Antonella Meloni
- Department of Radiology, Fondazione Monasterio/CNR, 56124 Pisa, Italy
- Department of Bioengineering, Fondazione Monasterio/CNR, 56124 Pisa, Italy
| | - Laura Pistoia
- Department of Radiology, Fondazione Monasterio/CNR, 56124 Pisa, Italy
| | - Giulia Degiorgi
- Department of Radiology, Fondazione Monasterio/CNR, 56124 Pisa, Italy
| | - Alberto Clemente
- Department of Radiology, Fondazione Monasterio/CNR, 56124 Pisa, Italy
| | - Carmelo De Gori
- Department of Radiology, Fondazione Monasterio/CNR, 56124 Pisa, Italy
| | - Vincenzo Positano
- Department of Radiology, Fondazione Monasterio/CNR, 56124 Pisa, Italy
- Department of Bioengineering, Fondazione Monasterio/CNR, 56124 Pisa, Italy
| | - Simona Celi
- BioCardioLab, Department of Bioengineering, Fondazione Monasterio/CNR, 54100 Massa, Italy
| | - Sergio Berti
- Cardiology Unit, Ospedale del Cuore, Fondazione Monasterio/CNR, 54100 Massa, Italy
| | - Michele Emdin
- Department of Cardiology, Fondazione Monasterio/CNR, 56124 Pisa, Italy
| | - Daniele Panetta
- Institute of Clinical Physiology, National Council of Research, 56124 Pisa, Italy
| | - Luca Menichetti
- Institute of Clinical Physiology, National Council of Research, 56124 Pisa, Italy
| | - Bruna Punzo
- Department of Radiology, IRCCS SynLab-SDN, 80131 Naples, Italy
| | - Carlo Cavaliere
- Department of Radiology, IRCCS SynLab-SDN, 80131 Naples, Italy
| | - Eduardo Bossone
- Department of Cardiology, Ospedale Cardarelli, 80131 Naples, Italy
| | - Luca Saba
- Department of Radiology, University Hospital, 09042 Monserrato, Italy
| | - Riccardo Cau
- Department of Radiology, University Hospital, 09042 Monserrato, Italy
| | - Ludovico La Grutta
- Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties-ProMISE, Department of Radiology, University Hospital "P. Giaccone", 90127 Palermo, Italy
| | - Erica Maffei
- Department of Radiology, Fondazione Monasterio/CNR, 56124 Pisa, Italy
| |
Collapse
|
7
|
Said M, Tavakoli C, Dumot C, Toupet K, Dong YC, Collomb N, Auxenfans C, Moisan A, Favier B, Chovelon B, Barbier EL, Jorgensen C, Cormode DP, Noël D, Brun E, Elleaume H, Wiart M, Detante O, Rome C, Auzély-Velty R. A novel injectable radiopaque hydrogel with potent properties for multicolor CT imaging in the context of brain and cartilage regenerative therapy. BIORXIV : THE PREPRINT SERVER FOR BIOLOGY 2023:2023.04.20.537520. [PMID: 37131613 PMCID: PMC10153246 DOI: 10.1101/2023.04.20.537520] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/04/2023]
Abstract
Cell therapy is promising to treat many conditions, including neurological and osteoarticular diseases. Encapsulation of cells within hydrogels facilitates cell delivery and can improve therapeutic effects. However, much work remains to be done to align treatment strategies with specific diseases. The development of imaging tools that enable monitoring cells and hydrogel independently is key to achieving this goal. Our objective herein is to longitudinally study an iodine-labeled hydrogel, incorporating gold-labeled stem cells, by bicolor CT imaging after in vivo injection in rodent brains or knees. To this aim, an injectable self-healing hyaluronic acid (HA) hydrogel with long-persistent radiopacity was formed by the covalent grafting of a clinical contrast agent on HA. The labeling conditions were tuned to achieve sufficient X-ray signal and to maintain the mechanical and self-healing properties as well as injectability of the original HA scaffold. The efficient delivery of both cells and hydrogel at the targeted sites was demonstrated by synchrotron K-edge subtraction-CT. The iodine labeling enabled to monitor the hydrogel biodistribution in vivo up to 3 days post-administration, which represents a technological first in the field of molecular CT imaging agents. This tool may foster the translation of combined cell-hydrogel therapies into the clinics.
Collapse
Affiliation(s)
- Moustoifa Said
- Univ. Grenoble Alpes, Centre de Recherches sur les Macromolécules Végétales (CERMAV-CNRS), 38041 Grenoble, France; Univ. Grenoble Alpes, Inserm, U1216, Grenoble Institut Neurosciences, 38000 Grenoble, France
| | - Clément Tavakoli
- Univ. Lyon 1, Inserm U1060, CarMeN Laboratory, 69600 Oullins, France; Univ. Grenoble Alpes, Inserm, UA7 Strobe, 38000 Grenoble, France
| | - Chloé Dumot
- Univ. Lyon 1, Inserm U1060, CarMeN Laboratory, 69600 Oullins, France
| | - Karine Toupet
- IRMB, Univ. Montpellier, INSERM, CHU Montpellier, Montpellier, France
| | - Yuxi Clara Dong
- Department of Radiology and Department of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States
| | - Nora Collomb
- Univ. Grenoble Alpes, Inserm, U1216, Grenoble Institut Neurosciences, 38000 Grenoble, France
| | | | - Anaïck Moisan
- Cell Therapy and Engineering Unit, EFS Rhone Alpes, 38330 Saint Ismier, France
| | - Bertrand Favier
- Univ. Grenoble Alpes, Translational Innovation in Medicine & Complexity, UMR552, 38700 La Tronche, France
| | - Benoit Chovelon
- Univ. Grenoble-Alpes, Departement de Pharmacochimie Moleculaire UMR 5063, 38400 Grenoble, France; Institut de Biologie et Pathologie, CHU de Grenoble-Alpes, 38700 La Tronche, France
| | - Emmanuel Luc Barbier
- Univ. Grenoble Alpes, Inserm, U1216, Grenoble Institut Neurosciences, 38000 Grenoble, France
| | | | - David Peter Cormode
- Department of Radiology and Department of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States
| | - Danièle Noël
- IRMB, Univ. Montpellier, INSERM, CHU Montpellier, Montpellier, France
| | - Emmanuel Brun
- Univ. Grenoble Alpes, Inserm, UA7 Strobe, 38000 Grenoble, France
| | - Hélène Elleaume
- Univ. Grenoble Alpes, Inserm, UA7 Strobe, 38000 Grenoble, France
| | - Marlène Wiart
- Univ. Lyon 1, Inserm U1060, CarMeN Laboratory, 69600 Oullins, France
| | - Olivier Detante
- Univ. Grenoble Alpes, Inserm, U1216, Grenoble Institut Neurosciences, 38000 Grenoble, France; CHU Grenoble Alpes, Stroke Unit, Department of Neurology, 38043 Grenoble, France
| | - Claire Rome
- Univ. Grenoble Alpes, Inserm, U1216, Grenoble Institut Neurosciences, 38000 Grenoble, France
| | - Rachel Auzély-Velty
- Univ. Grenoble Alpes, Centre de Recherches sur les Macromolécules Végétales (CERMAV-CNRS), 38041 Grenoble, France
| |
Collapse
|
8
|
Moghiseh M, Searle E, Dixit D, Kim J, Dong YC, Cormode DP, Butler A, Gieseg SP. Spectral Photon-Counting CT Imaging of Gold Nanoparticle Labelled Monocytes for Detection of Atherosclerosis: A Preclinical Study. Diagnostics (Basel) 2023; 13:diagnostics13030499. [PMID: 36766602 PMCID: PMC9914700 DOI: 10.3390/diagnostics13030499] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2022] [Revised: 01/20/2023] [Accepted: 01/24/2023] [Indexed: 01/31/2023] Open
Abstract
A key process in the development of atherosclerotic plaques is the recruitment of monocytes into the artery wall. Using spectral photon-counting computed tomography we examine whether monocyte deposition within the artery wall of ApoE-/- mouse can be detected. Primary mouse monocytes were labelled by incubating them with 15 nm gold nanoparticles coated with 11-mercaptoundecanoic acid The monocyte uptake of the particle was confirmed by electron microscopy of the cells before injection into 6-week-old apolipoprotein E deficient (ApoE-/-) mouse that had been fed with the Western diet for 10 weeks. Four days following injection, the mouse was sacrificed and imaged using a MARS spectral photon counting computed tomography scanner with a spectral range of 7 to 120 KeV with five energy bins. Imaging analysis showed the presence of X-ray dense material within the mouse aortic arch which was consistent with the spectral characteristic of gold rather than calcium. The imaging is interpreted as showing the deposition of gold nanoparticles containing monocytes within the mouse aorta. The results of our study determined that spectral photon-counting computed tomography could provide quantitative information about gold nanoparticles labelled monocytes in voxels of 90 × 90 × 90 µm3. The imaging was consistent with previous micro-CT and electron microscopy of mice using the same nanoparticles. This study demonstrates that spectral photon-counting computed tomography, using a MARS small bore scanner, can detect a fundamental atherogenic process within mouse models of atherogenesis. The present study demonstrates the feasibility of spectral photon-counting computed tomography as an emerging molecular imaging modality to detect atherosclerotic disease.
Collapse
Affiliation(s)
- Mahdieh Moghiseh
- Department of Radiology, University of Otago, Christchurch 9016, New Zealand
- MARS Bioimaging Ltd., Christchurch 8041, New Zealand
- Correspondence: (M.M.); (S.P.G.)
| | - Emily Searle
- MARS Bioimaging Ltd., Christchurch 8041, New Zealand
- Free Radical Biochemistry Laboratory, School of Biological Sciences, University of Canterbury, Christchurch 8041, New Zealand
- Department of Physics and Astronomy, University of Canterbury, Christchurch 8041, New Zealand
| | - Devyani Dixit
- MARS Bioimaging Ltd., Christchurch 8041, New Zealand
- Free Radical Biochemistry Laboratory, School of Biological Sciences, University of Canterbury, Christchurch 8041, New Zealand
| | - Johoon Kim
- Departments of Radiology, Bioengineering, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Yuxi C. Dong
- Departments of Radiology, Bioengineering, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - David P. Cormode
- Departments of Radiology, Bioengineering, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Anthony Butler
- Department of Radiology, University of Otago, Christchurch 9016, New Zealand
- MARS Bioimaging Ltd., Christchurch 8041, New Zealand
- Department of Physics and Astronomy, University of Canterbury, Christchurch 8041, New Zealand
- European Organization for Nuclear Research (CERN), 1211 Meyrin, Switzerland
| | - Steven P. Gieseg
- Department of Radiology, University of Otago, Christchurch 9016, New Zealand
- MARS Bioimaging Ltd., Christchurch 8041, New Zealand
- Free Radical Biochemistry Laboratory, School of Biological Sciences, University of Canterbury, Christchurch 8041, New Zealand
- European Organization for Nuclear Research (CERN), 1211 Meyrin, Switzerland
- Correspondence: (M.M.); (S.P.G.)
| | | |
Collapse
|
9
|
Tavakoli C, Cuccione E, Dumot C, Balegamire J, Si-Mohamed SA, Kim J, Crola-da-Silva C, Chevalier Y, Boussel L, Douek P, Cormode D, Elleaume H, Brun E, Wiart M. High-resolution synchrotron K-edge subtraction CT allows tracking and quantifying therapeutic cells and their scaffold in a rat model of focal cerebral injury and can serve as a reference for spectral photon counting CT. Nanotheranostics 2023; 7:176-186. [PMID: 36793350 PMCID: PMC9925349 DOI: 10.7150/ntno.79575] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2022] [Accepted: 12/29/2022] [Indexed: 02/15/2023] Open
Abstract
Background: The objective of this study was to demonstrate that synchrotron K-edge subtraction tomography (SKES-CT) can simultaneously track therapeutic cells and their encapsulating carrier, in vivo, in a rat model of focal brain injury using a dual-contrast agent approach. The second objective was to determine if SKES-CT could be used as a reference method for spectral photon counting tomography (SPCCT). Methods: Phantoms containing different concentrations of gold and iodine nanoparticles (AuNPS/INPs) were imaged with SKES-CT and SPCCT to assess their performances. A pre-clinical study was performed in rats with focal cerebral injury which intracerebrally received AuNPs-labelled therapeutic cells encapsulated in a INPs-labelled scaffold. Animals were imaged in vivo with SKES-CT and back-to-back with SPCCT. Results: SKES-CT revealed to be reliable for quantification of gold and iodine, whether alone or mixed. In the preclinical model, SKES-CT showed that AuNPs remained at the site of cell injection, while INPs expanded within and/or along the lesion border, suggesting dissociation of both components in the first days post-administration. Compared to SKES-CT, SPCCT was able to correctly locate gold, but not completely located iodine. When SKES-CT was used as reference, SPCCT gold quantification appeared very accurate both in vitro and in vivo. Iodine quantification by SPCCT was also quite accurate, albeit less so than for gold. Conclusion: We here provide the proof-of-concept that SKES-CT is a novel method of choice for performing dual-contrast agent imaging in the context of brain regenerative therapy. SKES-CT may also serve as ground truth for emerging technologies such as multicolour clinical SPCCT.
Collapse
Affiliation(s)
- Clément Tavakoli
- Univ Lyon, CarMeN Laboratory, INSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1, 69003, Lyon, France.,Univ. Grenoble Alpes, Inserm UA7 Strobe, Grenoble, France
| | - Elisa Cuccione
- Univ Lyon, CarMeN Laboratory, INSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1, 69003, Lyon, France
| | - Chloé Dumot
- Univ Lyon, CarMeN Laboratory, INSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1, 69003, Lyon, France.,Hospices Civils de Lyon, Lyon, France
| | - Joëlle Balegamire
- LAGEPP, University of Lyon 1, CNRS UMR 5007, 43 bd 11 Novembre, 69622 Villeurbanne, France
| | - Salim Aymeric Si-Mohamed
- Department of cardiovascular and thoracic radiology, Louis Pradel Hospital, Hospices Civils de Lyon, 59 Boulevard Pinel, 69500 Bron, France.,CREATIS, UMR 5220, Univ Lyon, INSA Lyon, University Claude Bernard Lyon 1, Lyon, France
| | - Johoon Kim
- Department of Radiology, University of Pennsylvania, Pennsylvania, United States
| | - Claire Crola-da-Silva
- Univ Lyon, CarMeN Laboratory, INSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1, 69003, Lyon, France
| | - Yves Chevalier
- LAGEPP, University of Lyon 1, CNRS UMR 5007, 43 bd 11 Novembre, 69622 Villeurbanne, France
| | - Loïc Boussel
- Department of cardiovascular and thoracic radiology, Louis Pradel Hospital, Hospices Civils de Lyon, 59 Boulevard Pinel, 69500 Bron, France.,CREATIS, UMR 5220, Univ Lyon, INSA Lyon, University Claude Bernard Lyon 1, Lyon, France
| | - Philippe Douek
- Department of cardiovascular and thoracic radiology, Louis Pradel Hospital, Hospices Civils de Lyon, 59 Boulevard Pinel, 69500 Bron, France.,CREATIS, UMR 5220, Univ Lyon, INSA Lyon, University Claude Bernard Lyon 1, Lyon, France
| | - David Cormode
- Department of Radiology, University of Pennsylvania, Pennsylvania, United States
| | | | - Emmanuel Brun
- Univ. Grenoble Alpes, Inserm UA7 Strobe, Grenoble, France
| | - Marlène Wiart
- Univ Lyon, CarMeN Laboratory, INSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1, 69003, Lyon, France.,CNRS, Lyon, France
| |
Collapse
|
10
|
Wiart M, Tavakoli C, Hubert V, Hristovska I, Dumot C, Parola S, Lerouge F, Chauveau F, Canet-Soulas E, Pascual O, Cormode DP, Brun E, Elleaume H. Use of metal-based contrast agents for in vivo MR and CT imaging of phagocytic cells in neurological pathologies. J Neurosci Methods 2023; 383:109729. [PMID: 36272462 DOI: 10.1016/j.jneumeth.2022.109729] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2022] [Revised: 09/27/2022] [Accepted: 10/17/2022] [Indexed: 11/30/2022]
Abstract
The activation of phagocytic cells is a hallmark of many neurological diseases. Imaging them in their 3-dimensional cerebral environment over time is crucial to better understand their role in disease pathogenesis and to monitor their potential therapeutic effects. Phagocytic cells have the ability to internalize metal-based contrast agents both in vitro and in vivo and can thus be tracked by magnetic resonance imaging (MRI) or computed tomography (CT). In this review article, we summarize the different labelling strategies, contrast agents, and in vivo imaging modalities that can be used to monitor cells with phagocytic activity in the central nervous system using MRI and CT, with a focus on clinical applications. Metal-based nanoparticle contrast agents such as gadolinium, gold and iron are ideal candidates for these applications as they have favourable magnetic and/or radiopaque properties and can be fine-tuned for optimal uptake by phagocytic cells. However, they also come with downsides due to their potential toxicity, especially in the brain where they might accumulate. We therefore conclude our review by discussing the pitfalls, safety and potential for clinical translation of these metal-based neuroimaging techniques. Early results in patients with neuropathologies such as multiple sclerosis, stroke, trauma, cerebral aneurysm and glioblastoma are promising. If the challenges represented by safety issues are overcome, phagocytic cells imaging will be a very valuable tool for studying and understanding the inflammatory response and evaluating treatments that aim at mitigating this response in patients with neurological diseases.
Collapse
Affiliation(s)
- Marlène Wiart
- Univ. Lyon, CarMeN Laboratory, INSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1, 69003 Lyon, France; CNRS, Lyon, France.
| | - Clément Tavakoli
- Univ. Lyon, CarMeN Laboratory, INSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1, 69003 Lyon, France; Univ. Grenoble Alpes, INSERM UA7 STROBE, 38000 Grenoble, France
| | - Violaine Hubert
- Univ. Lyon, CarMeN Laboratory, INSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1, 69003 Lyon, France
| | | | - Chloé Dumot
- Univ. Lyon, CarMeN Laboratory, INSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1, 69003 Lyon, France; Hospices Civils de Lyon, Lyon, France
| | - Stéphane Parola
- Université de Lyon, Ecole Normale Supérieure de Lyon, CNRS UMR 5182, Université Lyon 1, Laboratoire de Chimie, 46 allée d'Italie, 69364 Lyon, France
| | - Frédéric Lerouge
- Université de Lyon, Ecole Normale Supérieure de Lyon, CNRS UMR 5182, Université Lyon 1, Laboratoire de Chimie, 46 allée d'Italie, 69364 Lyon, France
| | - Fabien Chauveau
- CNRS, Lyon, France; Univ. Lyon, Lyon Neurosciences Research Center, CNRS UMR5292, INSERM U1028, Université Claude Bernard Lyon 1, 69003 Lyon, France
| | - Emmanuelle Canet-Soulas
- Univ. Lyon, CarMeN Laboratory, INSERM, INRA, INSA Lyon, Université Claude Bernard Lyon 1, 69003 Lyon, France
| | | | - David P Cormode
- Department of Radiology, University of Pennsylvania, Pennsylvania, United States
| | - Emmanuel Brun
- Univ. Grenoble Alpes, INSERM UA7 STROBE, 38000 Grenoble, France
| | - Hélène Elleaume
- Univ. Grenoble Alpes, INSERM UA7 STROBE, 38000 Grenoble, France
| |
Collapse
|
11
|
Li Y, Younis MH, Wang H, Zhang J, Cai W, Ni D. Spectral computed tomography with inorganic nanomaterials: State-of-the-art. Adv Drug Deliv Rev 2022; 189:114524. [PMID: 36058350 PMCID: PMC9664656 DOI: 10.1016/j.addr.2022.114524] [Citation(s) in RCA: 16] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2022] [Revised: 08/09/2022] [Accepted: 08/27/2022] [Indexed: 01/24/2023]
Abstract
Recently, spectral computed tomography (CT) technology has received great interest in the field of radiology. Spectral CT imaging utilizes the distinct, energy-dependent X-ray absorption properties of substances in order to provide additional imaging information. Dual-energy CT and multi-energy CT (Spectral CT) are capable of constructing monochromatic energy images, material separation images, energy spectrum curves, constructing effective atomic number maps, and more. However, poor contrast, due to neighboring X-ray attenuation of organs and tissues, is still a challenge to spectral CT. Hence, contrast agents (CAs) are applied for better differentiation of a given region of interest (ROI). Currently, many different kinds of inorganic nanoparticulate CAs for spectral CT have been developed due to the limitations of clinical iodine (I)-based contrast media, leading to the conclusion that inorganic nanomedicine applied to spectral CT will be a powerful collaboration both in basic research and in clinics. In this review, the underlying principles and types of spectral CT techniques are discussed, and some evolving clinical diagnosis applications of spectral CT techniques are introduced. In particular, recent developments in inorganic CAs used for spectral CT are summarized. Finally, the challenges and future developments of inorganic nanomedicine in spectral CT are briefly discussed.
Collapse
Affiliation(s)
- Yuhan Li
- School of Medicine, Shanghai University, No. 99 Shangda Rd, Shanghai 200444, PR China
| | - Muhsin H Younis
- Departments of Radiology and Medical Physics, University of Wisconsin-Madison, WI 53705, United States
| | - Han Wang
- Department of Orthopaedics, Shanghai Key Laboratory for Prevention and Treatment of Bone and Joint Diseases, Shanghai Institute of Traumatology and Orthopaedics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197, Ruijin 2nd Rd, Shanghai 200025, PR China
| | - Jian Zhang
- School of Medicine, Shanghai University, No. 99 Shangda Rd, Shanghai 200444, PR China; Shanghai Universal Medical Imaging Diagnostic Center, Bldg 8, No. 406 Guilin Rd, Shanghai 200233, PR China.
| | - Weibo Cai
- Departments of Radiology and Medical Physics, University of Wisconsin-Madison, WI 53705, United States.
| | - Dalong Ni
- Department of Orthopaedics, Shanghai Key Laboratory for Prevention and Treatment of Bone and Joint Diseases, Shanghai Institute of Traumatology and Orthopaedics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197, Ruijin 2nd Rd, Shanghai 200025, PR China.
| |
Collapse
|
12
|
Dong YC, Kumar A, Rosario-Berríos DN, Si-Mohamed S, Hsu JC, Nieves LM, Douek P, Noël PB, Cormode DP. Ytterbium Nanoparticle Contrast Agents for Conventional and Spectral Photon-Counting CT and Their Applications for Hydrogel Imaging. ACS APPLIED MATERIALS & INTERFACES 2022; 14:39274-39284. [PMID: 35975982 PMCID: PMC9513702 DOI: 10.1021/acsami.2c12354] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
Significant work has been done to develop nanoparticle contrast agents for computed tomography (CT), with a focus on identifying safer and more effective formulations. Contrast agents for spectral photon-counting computed tomography (SPCCT), a fast-growing imaging modality derived from conventional CT, have also recently gained considerable attention. In this study, we explored the synthesis of ultrasmall ytterbium nanoparticles (YbNP) and demonstrated that, potentially, they can be used as conventional CT and SPCCT contrast agents. These nanoparticles were tested in vitro for their cytotoxicity and contrast-generating properties with a variety of imaging systems. When scanned with conventional CT and SPCCT at clinically relevant energies, YbNP are significantly more attenuating than gold nanoparticles (AuNP), the contrast agents that have been most well studied. Furthermore, YbNP were studied for their potential application for labeling and monitoring hydrogels. The presence of the YbNP payload in hydrogels allowed for hydrogel localization and tracking in vivo. Additionally, the in vivo imaging results revealed that YbNP generate higher contrast when compared to AuNP used as a label. In summary, this is the first research study to examine ultrasmall YbNP as conventional CT and SPCCT contrast agents, as well as using them in a hydrogel system to make it radiopaque. These findings underscore YbNP's utility as CT and SPCCT contrast agents, as well as their potential for tracking hydrogels in vivo.
Collapse
Affiliation(s)
- Yuxi C Dong
- Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States
- Department of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States
| | - Ananyaa Kumar
- Department of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States
| | - Derick N Rosario-Berríos
- Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States
- Department of Biochemistry and Molecular Biophysics, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States
| | - Salim Si-Mohamed
- CREATIS, CNRS UMR 5220, INSERM U1206, INSA, University Claude Bernard Lyon 1, F69621 Lyon, France
| | - Jessica C Hsu
- Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States
- Department of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States
| | - Lenitza M Nieves
- Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States
- Department of Biochemistry and Molecular Biophysics, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States
| | - Philippe Douek
- CREATIS, CNRS UMR 5220, INSERM U1206, INSA, University Claude Bernard Lyon 1, F69621 Lyon, France
| | - Peter B Noël
- Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States
| | - David P Cormode
- Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States
- Department of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States
| |
Collapse
|
13
|
Xue Z, Mei D, Zhang L. Advances in single-cell nanoencapsulation and applications in diseases. J Microencapsul 2022; 39:481-494. [PMID: 35998209 DOI: 10.1080/02652048.2022.2111472] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
Abstract
Single-cell nanoencapsulation is a method of coating the surface of single cell with nanomaterials. In the early 20th century, with the introduction of various types of organic or inorganic nano-polymer materials, the selection of cell types, and the functional modification of the outer coating, this technology has gradually matured. Typical preparation methods include interfacial polycondensation, complex condensation, spray drying, microdroplet ejection, and layer-by-layer (LbL) self-assembly. The LbL assembly technology utilises nanomaterials with opposite charges deposited on cells by strong interaction (electrostatic interaction) or weak interaction (hydrogen bonding, hydrophobic interaction), which drives compounds to spontaneously form films with complete structure, stable performance and unique functions on cells. According to the needs of the disease, choosing appropriate cell types and biocompatible and biodegradable nanomaterials could achieve the purpose of promoting cell proliferation, immune isolation, reducing phagocytosis of the reticuloendothelial system, prolonging the circulation time in vivo, and avoiding repeated administration. Therefore, encapsulated cells could be utilised in various biomedical fields, such as cell catalysis, biotherapy, vaccine manufacturing and antitumor therapy. This article reviews cell nanoencapsulation therapies for diseases, including the various cell sources used, nanoencapsulation technology and the latest advances in preclinical and clinical research.
Collapse
Affiliation(s)
- Ziyang Xue
- Institute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Centre of Anti-Inflammatory and Immune Medicine, Center of Rheumatoid Arthritis of Anhui Medical University, Hefei, China
| | - Dan Mei
- Institute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Centre of Anti-Inflammatory and Immune Medicine, Center of Rheumatoid Arthritis of Anhui Medical University, Hefei, China
| | - Lingling Zhang
- Institute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Centre of Anti-Inflammatory and Immune Medicine, Center of Rheumatoid Arthritis of Anhui Medical University, Hefei, China
| |
Collapse
|
14
|
Hubert V, Hristovska I, Karpati S, Benkeder S, Dey A, Dumot C, Amaz C, Chounlamountri N, Watrin C, Comte J, Chauveau F, Brun E, Marche P, Lerouge F, Parola S, Berthezène Y, Vorup‐Jensen T, Pascual O, Wiart M. Multimodal Imaging with NanoGd Reveals Spatiotemporal Features of Neuroinflammation after Experimental Stroke. ADVANCED SCIENCE (WEINHEIM, BADEN-WURTTEMBERG, GERMANY) 2021; 8:e2101433. [PMID: 34197055 PMCID: PMC8425862 DOI: 10.1002/advs.202101433] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/07/2021] [Revised: 05/12/2021] [Indexed: 05/09/2023]
Abstract
The purpose of this study is to propose and validate a preclinical in vivo magnetic resonance imaging (MRI) tool to monitor neuroinflammation following ischemic stroke, based on injection of a novel multimodal nanoprobe, NanoGd, specifically designed for internalization by phagocytic cells. First, it is verified that NanoGd is efficiently internalized by microglia in vitro. In vivo MRI coupled with intravenous injection of NanoGd in a permanent middle cerebral artery occlusion mouse model results in hypointense signals in the ischemic lesion. In these mice, longitudinal two-photon intravital microscopy shows NanoGd internalization by activated CX3CR1-GFP/+ cells. Ex vivo analysis, including phase contrast imaging with synchrotron X-ray, histochemistry, and transmission electron microscopy corroborate NanoGd accumulation within the ischemic lesion and uptake by immune phagocytic cells. Taken together, these results confirm the potential of NanoGd-enhanced MRI as an imaging biomarker of neuroinflammation at the subacute stage of ischemic stroke. As far as it is known, this work is the first to decipher the working mechanism of MR signals induced by a nanoparticle passively targeted at phagocytic cells by performing intravital microscopy back-to-back with MRI. Furthermore, using a gadolinium-based rather than an iron-based contrast agent raises future perspectives for the development of molecular imaging with emerging computed tomography technologies.
Collapse
Affiliation(s)
- Violaine Hubert
- Univ‐LyonIRIS TeamCarMeN LaboratoryInserm U1060INRA U1397INSA LyonUniversité Claude Bernard Lyon 1Groupement Hospitalier Est59 bd. PinelBron69500France
| | - Ines Hristovska
- SYNATAC TeamInstitut NeuroMyoGèneUniversité Claude Bernard Lyon 1CNRS UMR 5310, INSERM U1217Faculté de Médecine et de Pharmacie8 avenue RockefellerLyon69008France
| | - Szilvia Karpati
- Université de LyonÉcole Normale Supérieure de LyonCNRS UMR 5182Université Claude Bernard Lyon 1Laboratoire de ChimieLyonF69342France
| | - Sarah Benkeder
- SYNATAC TeamInstitut NeuroMyoGèneUniversité Claude Bernard Lyon 1CNRS UMR 5310, INSERM U1217Faculté de Médecine et de Pharmacie8 avenue RockefellerLyon69008France
| | - Arindam Dey
- Institut pour l'Avancée des BiosciencesCentre de Recherche UGA / Inserm U 1209 / CNRS UMR 5309Site Santé ‐ Allée des AlpesLa Tronche38700France
| | - Chloé Dumot
- Univ‐LyonIRIS TeamCarMeN LaboratoryInserm U1060INRA U1397INSA LyonUniversité Claude Bernard Lyon 1Groupement Hospitalier Est59 bd. PinelBron69500France
| | - Camille Amaz
- Clinical Investigation CenterHospices Civils de LyonLouis Pradel Hospital28 avenue Doyen LépineBron69500France
| | - Naura Chounlamountri
- SYNATAC TeamInstitut NeuroMyoGèneUniversité Claude Bernard Lyon 1CNRS UMR 5310, INSERM U1217Faculté de Médecine et de Pharmacie8 avenue RockefellerLyon69008France
| | - Chantal Watrin
- SYNATAC TeamInstitut NeuroMyoGèneUniversité Claude Bernard Lyon 1CNRS UMR 5310, INSERM U1217Faculté de Médecine et de Pharmacie8 avenue RockefellerLyon69008France
| | - Jean‐Christophe Comte
- FORGETTING TeamLyon Neuroscience Research Center (CRNL)CNRS UMR5292INSERM U1028Université Claude Bernard Lyon 1Centre Hospitalier Le Vinatier ‐ Bâtiment 462 ‐ Neurocampus Michel Jouvet95 boulevard PinelBron69675France
| | - Fabien Chauveau
- Université de LyonLyon Neuroscience Research Center (CRNL)CNRS UMR5292INSERM U1028Université Claude Bernard Lyon 1Groupement Hospitalier Est ‐ CERMEP59 bd PinelBron Cedex69677France
| | - Emmanuel Brun
- Synchrotron Radiation for Biomedical Research (STROBE)UA7 INSERMUniversité Grenoble AlpesMedical Beamline at the European Synchrotron Radiation Facility71 Avenue des MartyrsGrenoble Cedex 938043France
| | - Patrice Marche
- Institut pour l'Avancée des BiosciencesCentre de Recherche UGA / Inserm U 1209 / CNRS UMR 5309Site Santé ‐ Allée des AlpesLa Tronche38700France
| | - Fréderic Lerouge
- Université de LyonÉcole Normale Supérieure de LyonCNRS UMR 5182Université Claude Bernard Lyon 1Laboratoire de ChimieLyonF69342France
| | - Stéphane Parola
- Université de LyonÉcole Normale Supérieure de LyonCNRS UMR 5182Université Claude Bernard Lyon 1Laboratoire de ChimieLyonF69342France
| | - Yves Berthezène
- Univ‐LyonCreatis LaboratoryCNRS UMR5220Inserm U1044INSA LyonVilleurbanne Cedex69621France
| | - Thomas Vorup‐Jensen
- Department of BiomedicineBiophysical Immunology LaboratoryAarhus UniversityAarhus CDK‐8000Denmark
| | - Olivier Pascual
- SYNATAC TeamInstitut NeuroMyoGèneUniversité Claude Bernard Lyon 1CNRS UMR 5310, INSERM U1217Faculté de Médecine et de Pharmacie8 avenue RockefellerLyon69008France
| | - Marlène Wiart
- Univ‐LyonIRIS TeamCarMeN LaboratoryInserm U1060INRA U1397INSA LyonUniversité Claude Bernard Lyon 1Groupement Hospitalier Est59 bd. PinelBron69500France
| |
Collapse
|
15
|
Sawall S, Amato C, Klein L, Wehrse E, Maier J, Kachelrieß M. Toward molecular imaging using spectral photon-counting computed tomography? Curr Opin Chem Biol 2021; 63:163-170. [PMID: 34051510 DOI: 10.1016/j.cbpa.2021.04.002] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2021] [Accepted: 04/07/2021] [Indexed: 12/22/2022]
Abstract
Molecular imaging is a valuable tool in drug discovery and development, early screening and diagnosis of diseases, and therapy assessment among others. Although many different imaging modalities are in use today, molecular imaging with computed tomography (CT) is still challenging owing to its low sensitivity and soft tissue contrast compared with other modalities. Recent technical advances, particularly the introduction of spectral photon-counting detectors, might allow overcoming these challenges. Herein, the fundamentals and recent advances in CT relevant to molecular imaging are reviewed and potential future preclinical and clinical applications are highlighted. The review concludes with a discussion of potential future advancements of CT for molecular imaging.
Collapse
Affiliation(s)
- Stefan Sawall
- Division of X-Ray Imaging and CT, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg, 69120, Baden-Württemberg, Germany; Medical Faculty, Ruprecht-Karls-University Heidelberg, Im Neuenheimer Feld 672, Heidelberg, 69120, Baden-Württemberg, Germany.
| | - Carlo Amato
- Division of X-Ray Imaging and CT, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg, 69120, Baden-Württemberg, Germany; Medical Faculty, Ruprecht-Karls-University Heidelberg, Im Neuenheimer Feld 672, Heidelberg, 69120, Baden-Württemberg, Germany
| | - Laura Klein
- Division of X-Ray Imaging and CT, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg, 69120, Baden-Württemberg, Germany; Physical Faculty, Ruprecht-Karls-University Heidelberg, Im Neuenheimer Feld 226, Heidelberg, 69120, Baden-Württemberg, Germany
| | - Eckhard Wehrse
- Division of Radiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg, 69120, Baden-Württemberg, Germany; Medical Faculty, Ruprecht-Karls-University Heidelberg, Im Neuenheimer Feld 672, Heidelberg, 69120, Baden-Württemberg, Germany
| | - Joscha Maier
- Division of X-Ray Imaging and CT, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg, 69120, Baden-Württemberg, Germany
| | - Marc Kachelrieß
- Division of X-Ray Imaging and CT, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg, 69120, Baden-Württemberg, Germany; Medical Faculty, Ruprecht-Karls-University Heidelberg, Im Neuenheimer Feld 672, Heidelberg, 69120, Baden-Württemberg, Germany
| |
Collapse
|
16
|
Si-Mohamed SA, Sigovan M, Hsu JC, Tatard-Leitman V, Chalabreysse L, Naha PC, Garrivier T, Dessouky R, Carnaru M, Boussel L, Cormode DP, Douek PC. In Vivo Molecular K-Edge Imaging of Atherosclerotic Plaque Using Photon-counting CT. Radiology 2021; 300:98-107. [PMID: 33944628 PMCID: PMC8217298 DOI: 10.1148/radiol.2021203968] [Citation(s) in RCA: 47] [Impact Index Per Article: 15.7] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
Background Macrophage burden is a major factor in the risk of atherosclerotic plaque rupture, and its evaluation remains challenging with molecular noninvasive imaging approaches. Photon-counting CT (PCCT) with k-edge imaging aims to allow for the specific detection of macrophages using gold nanoparticles. Purpose To perform k-edge imaging in combination with gold nanoparticles to detect and quantify the macrophage burden within the atherosclerotic aortas of rabbits. Materials and Methods Atherosclerotic and control New Zealand white rabbits were imaged before and at several time points up to 2 days after intravenous injection of gold nanoparticles (3.5 mL/kg, 65 mg gold per milliliter). Aortic CT angiography was performed at the end of the follow-up using an intravenous injection of an iodinated contrast material. Gold k-edge and conventional CT images were reconstructed for qualitative and quantitative assessment of the macrophage burden. PCCT imaging results were compared with findings at histologic examination, quantitative histomorphometry, transmission electron microscopy, and quantitative inductively coupled plasma optical emission spectrometry. Pearson correlations between the macrophage area measured in immunostained sections and the concentration of gold and attenuation measured in the corresponding PCCT sections were calculated. Results Seven rabbits with atherosclerosis and four control rabbits without atherosclerosis were analyzed. In atherosclerotic rabbits, calcifications were observed along the aortic wall before injection. At 2 days after injection of gold nanoparticles, only gold k-edge images allowed for the distinction of plaque enhancement within calcifications and for lumen enhancement during angiography. A good correlation was observed between the gold concentration measured within the wall and the macrophage area in 35 plaques (five per rabbit) (r = 0.82; 95% CI: 0.67, 0.91; P < .001), which was higher than that observed on conventional CT images (r = 0.41; 95% CI: 0.09, 0.65; P = .01). Transmission electron microscopy and inductively coupled plasma optical emission spectrometry analyses confirmed the gold k-edge imaging findings. Conclusion Photon-counting CT with gold nanoparticles allowed for the noninvasive evaluation of both molecular and anatomic information in vivo in rabbits with atherosclerotic plaques. Published under a CC BY 4.0 license. Online supplemental material is available for this article. See also the editorial by Leiner in this issue.
Collapse
Affiliation(s)
- Salim A Si-Mohamed
- From the University of Lyon, National Institute of Applied Sciences of Lyon, University Claude Bernard Lyon 1, Jean Monnet University-Saint Etienne, French National Centre for Scientific Research, Institut national de la santé et de la recherche médicale, Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé Unité mixte de recherche 5220, U1206, F-69621, Lyon, France (S.A.S.M., M.S., V.T.L., R.D., L.B., P.C.D.); Departments of Radiology (S.A.S.M., T.G., L.B., P.C.D.) and Pathology (L.C.), Hospices Civils de Lyon, Lyon, France; Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pa (J.C.H., P.C.N., D.P.C.); Department of Radiology, Faculty of Medicine, Zagazig University, Egypt (R.D.); and Department of Rheumatology, Allergy, and Immunology, Yale University, New Haven, Conn (M.C.)
| | - Monica Sigovan
- From the University of Lyon, National Institute of Applied Sciences of Lyon, University Claude Bernard Lyon 1, Jean Monnet University-Saint Etienne, French National Centre for Scientific Research, Institut national de la santé et de la recherche médicale, Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé Unité mixte de recherche 5220, U1206, F-69621, Lyon, France (S.A.S.M., M.S., V.T.L., R.D., L.B., P.C.D.); Departments of Radiology (S.A.S.M., T.G., L.B., P.C.D.) and Pathology (L.C.), Hospices Civils de Lyon, Lyon, France; Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pa (J.C.H., P.C.N., D.P.C.); Department of Radiology, Faculty of Medicine, Zagazig University, Egypt (R.D.); and Department of Rheumatology, Allergy, and Immunology, Yale University, New Haven, Conn (M.C.)
| | - Jessica C Hsu
- From the University of Lyon, National Institute of Applied Sciences of Lyon, University Claude Bernard Lyon 1, Jean Monnet University-Saint Etienne, French National Centre for Scientific Research, Institut national de la santé et de la recherche médicale, Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé Unité mixte de recherche 5220, U1206, F-69621, Lyon, France (S.A.S.M., M.S., V.T.L., R.D., L.B., P.C.D.); Departments of Radiology (S.A.S.M., T.G., L.B., P.C.D.) and Pathology (L.C.), Hospices Civils de Lyon, Lyon, France; Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pa (J.C.H., P.C.N., D.P.C.); Department of Radiology, Faculty of Medicine, Zagazig University, Egypt (R.D.); and Department of Rheumatology, Allergy, and Immunology, Yale University, New Haven, Conn (M.C.)
| | - Valérie Tatard-Leitman
- From the University of Lyon, National Institute of Applied Sciences of Lyon, University Claude Bernard Lyon 1, Jean Monnet University-Saint Etienne, French National Centre for Scientific Research, Institut national de la santé et de la recherche médicale, Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé Unité mixte de recherche 5220, U1206, F-69621, Lyon, France (S.A.S.M., M.S., V.T.L., R.D., L.B., P.C.D.); Departments of Radiology (S.A.S.M., T.G., L.B., P.C.D.) and Pathology (L.C.), Hospices Civils de Lyon, Lyon, France; Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pa (J.C.H., P.C.N., D.P.C.); Department of Radiology, Faculty of Medicine, Zagazig University, Egypt (R.D.); and Department of Rheumatology, Allergy, and Immunology, Yale University, New Haven, Conn (M.C.)
| | - Lara Chalabreysse
- From the University of Lyon, National Institute of Applied Sciences of Lyon, University Claude Bernard Lyon 1, Jean Monnet University-Saint Etienne, French National Centre for Scientific Research, Institut national de la santé et de la recherche médicale, Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé Unité mixte de recherche 5220, U1206, F-69621, Lyon, France (S.A.S.M., M.S., V.T.L., R.D., L.B., P.C.D.); Departments of Radiology (S.A.S.M., T.G., L.B., P.C.D.) and Pathology (L.C.), Hospices Civils de Lyon, Lyon, France; Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pa (J.C.H., P.C.N., D.P.C.); Department of Radiology, Faculty of Medicine, Zagazig University, Egypt (R.D.); and Department of Rheumatology, Allergy, and Immunology, Yale University, New Haven, Conn (M.C.)
| | - Pratap C Naha
- From the University of Lyon, National Institute of Applied Sciences of Lyon, University Claude Bernard Lyon 1, Jean Monnet University-Saint Etienne, French National Centre for Scientific Research, Institut national de la santé et de la recherche médicale, Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé Unité mixte de recherche 5220, U1206, F-69621, Lyon, France (S.A.S.M., M.S., V.T.L., R.D., L.B., P.C.D.); Departments of Radiology (S.A.S.M., T.G., L.B., P.C.D.) and Pathology (L.C.), Hospices Civils de Lyon, Lyon, France; Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pa (J.C.H., P.C.N., D.P.C.); Department of Radiology, Faculty of Medicine, Zagazig University, Egypt (R.D.); and Department of Rheumatology, Allergy, and Immunology, Yale University, New Haven, Conn (M.C.)
| | - Thibaut Garrivier
- From the University of Lyon, National Institute of Applied Sciences of Lyon, University Claude Bernard Lyon 1, Jean Monnet University-Saint Etienne, French National Centre for Scientific Research, Institut national de la santé et de la recherche médicale, Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé Unité mixte de recherche 5220, U1206, F-69621, Lyon, France (S.A.S.M., M.S., V.T.L., R.D., L.B., P.C.D.); Departments of Radiology (S.A.S.M., T.G., L.B., P.C.D.) and Pathology (L.C.), Hospices Civils de Lyon, Lyon, France; Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pa (J.C.H., P.C.N., D.P.C.); Department of Radiology, Faculty of Medicine, Zagazig University, Egypt (R.D.); and Department of Rheumatology, Allergy, and Immunology, Yale University, New Haven, Conn (M.C.)
| | - Riham Dessouky
- From the University of Lyon, National Institute of Applied Sciences of Lyon, University Claude Bernard Lyon 1, Jean Monnet University-Saint Etienne, French National Centre for Scientific Research, Institut national de la santé et de la recherche médicale, Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé Unité mixte de recherche 5220, U1206, F-69621, Lyon, France (S.A.S.M., M.S., V.T.L., R.D., L.B., P.C.D.); Departments of Radiology (S.A.S.M., T.G., L.B., P.C.D.) and Pathology (L.C.), Hospices Civils de Lyon, Lyon, France; Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pa (J.C.H., P.C.N., D.P.C.); Department of Radiology, Faculty of Medicine, Zagazig University, Egypt (R.D.); and Department of Rheumatology, Allergy, and Immunology, Yale University, New Haven, Conn (M.C.)
| | - Miruna Carnaru
- From the University of Lyon, National Institute of Applied Sciences of Lyon, University Claude Bernard Lyon 1, Jean Monnet University-Saint Etienne, French National Centre for Scientific Research, Institut national de la santé et de la recherche médicale, Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé Unité mixte de recherche 5220, U1206, F-69621, Lyon, France (S.A.S.M., M.S., V.T.L., R.D., L.B., P.C.D.); Departments of Radiology (S.A.S.M., T.G., L.B., P.C.D.) and Pathology (L.C.), Hospices Civils de Lyon, Lyon, France; Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pa (J.C.H., P.C.N., D.P.C.); Department of Radiology, Faculty of Medicine, Zagazig University, Egypt (R.D.); and Department of Rheumatology, Allergy, and Immunology, Yale University, New Haven, Conn (M.C.)
| | - Loic Boussel
- From the University of Lyon, National Institute of Applied Sciences of Lyon, University Claude Bernard Lyon 1, Jean Monnet University-Saint Etienne, French National Centre for Scientific Research, Institut national de la santé et de la recherche médicale, Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé Unité mixte de recherche 5220, U1206, F-69621, Lyon, France (S.A.S.M., M.S., V.T.L., R.D., L.B., P.C.D.); Departments of Radiology (S.A.S.M., T.G., L.B., P.C.D.) and Pathology (L.C.), Hospices Civils de Lyon, Lyon, France; Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pa (J.C.H., P.C.N., D.P.C.); Department of Radiology, Faculty of Medicine, Zagazig University, Egypt (R.D.); and Department of Rheumatology, Allergy, and Immunology, Yale University, New Haven, Conn (M.C.)
| | - David P Cormode
- From the University of Lyon, National Institute of Applied Sciences of Lyon, University Claude Bernard Lyon 1, Jean Monnet University-Saint Etienne, French National Centre for Scientific Research, Institut national de la santé et de la recherche médicale, Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé Unité mixte de recherche 5220, U1206, F-69621, Lyon, France (S.A.S.M., M.S., V.T.L., R.D., L.B., P.C.D.); Departments of Radiology (S.A.S.M., T.G., L.B., P.C.D.) and Pathology (L.C.), Hospices Civils de Lyon, Lyon, France; Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pa (J.C.H., P.C.N., D.P.C.); Department of Radiology, Faculty of Medicine, Zagazig University, Egypt (R.D.); and Department of Rheumatology, Allergy, and Immunology, Yale University, New Haven, Conn (M.C.)
| | - Philippe C Douek
- From the University of Lyon, National Institute of Applied Sciences of Lyon, University Claude Bernard Lyon 1, Jean Monnet University-Saint Etienne, French National Centre for Scientific Research, Institut national de la santé et de la recherche médicale, Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé Unité mixte de recherche 5220, U1206, F-69621, Lyon, France (S.A.S.M., M.S., V.T.L., R.D., L.B., P.C.D.); Departments of Radiology (S.A.S.M., T.G., L.B., P.C.D.) and Pathology (L.C.), Hospices Civils de Lyon, Lyon, France; Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pa (J.C.H., P.C.N., D.P.C.); Department of Radiology, Faculty of Medicine, Zagazig University, Egypt (R.D.); and Department of Rheumatology, Allergy, and Immunology, Yale University, New Haven, Conn (M.C.)
| |
Collapse
|
17
|
Pawelec KM, Chakravarty S, Hix JML, Perry KL, van Holsbeeck L, Fajardo R, Shapiro EM. Design Considerations to Facilitate Clinical Radiological Evaluation of Implantable Biomedical Structures. ACS Biomater Sci Eng 2021; 7:718-726. [PMID: 33449622 PMCID: PMC8670580 DOI: 10.1021/acsbiomaterials.0c01439] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Clinical effectiveness of implantable medical devices would be improved with in situ monitoring to ensure device positioning, determine subsequent damage, measure biodegradation, and follow healing. While standard clinical imaging protocols are appropriate for diagnosing disease and injury, these protocols have not been vetted for imaging devices. This study investigated how radiologists use clinical imaging to detect the location and integrity of implanted devices and whether embedding nanoparticle contrast agents into devices can improve assessment. To mimic the variety of devices available, phantoms from hydrophobic polymer films and hydrophilic gels were constructed, with and without computed tomography (CT)-visible TaOx and magnetic resonance imaging (MRI)-visible Fe3O4 nanoparticles. Some phantoms were purposely damaged by nick or transection. Phantoms were implanted in vitro into tissue and imaged with clinical CT, MRI, and ultrasound. In a blinded study, radiologists independently evaluated whether phantoms were present, assessed the type, and diagnosed whether phantoms were damaged or intact. Radiologists identified the location of phantoms 80% of the time. However, without incorporated nanoparticles, radiologists correctly assessed damage in only 54% of cases. With an incorporated imaging agent, the percentage jumped to 86%. The imaging technique which was most useful to radiologists varied with the properties of phantoms. With benefits and drawbacks to all three imaging modalities, future implanted devices should be engineered for visibility in the modality which best fits the treated tissue, the implanted device's physical location, and the type of required information. Imaging protocols should also be tailored to best exploit the properties of the imaging agents.
Collapse
Affiliation(s)
- Kendell M Pawelec
- Department of Radiology, Michigan State University, East Lansing, Michigan 48824, United States
| | - Shatadru Chakravarty
- Department of Radiology, Michigan State University, East Lansing, Michigan 48824, United States
| | - Jeremy M L Hix
- Department of Radiology, Michigan State University, East Lansing, Michigan 48824, United States
| | - Karen L Perry
- College of Veterinary Medicine, Michigan State University, East Lansing, Michigan 48824, United States
| | - Lodewijk van Holsbeeck
- Department of Radiology, Michigan State University, East Lansing, Michigan 48824, United States
| | - Ryan Fajardo
- Department of Radiology, Michigan State University, East Lansing, Michigan 48824, United States
| | - Erik M Shapiro
- Department of Radiology, Michigan State University, East Lansing, Michigan 48824, United States
| |
Collapse
|
18
|
Berry DB, Englund EK, Chen S, Frank LR, Ward SR. Medical imaging of tissue engineering and regenerative medicine constructs. Biomater Sci 2021; 9:301-314. [PMID: 32776044 PMCID: PMC8262082 DOI: 10.1039/d0bm00705f] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Advancement of tissue engineering and regenerative medicine (TERM) strategies to replicate tissue structure and function has led to the need for noninvasive assessment of key outcome measures of a construct's state, biocompatibility, and function. Histology based approaches are traditionally used in pre-clinical animal experiments, but are not always feasible or practical if a TERM construct is going to be tested for human use. In order to transition these therapies from benchtop to bedside, rigorously validated imaging techniques must be utilized that are sensitive to key outcome measures that fulfill the FDA standards for TERM construct evaluation. This review discusses key outcome measures for TERM constructs and various clinical- and research-based imaging techniques that can be used to assess them. Potential applications and limitations of these techniques are discussed, as well as resources for the processing, analysis, and interpretation of biomedical images.
Collapse
Affiliation(s)
- David B Berry
- Departments of NanoEngineering, University of California, San Diego, USA.
| | | | | | | | | |
Collapse
|
19
|
Nicolson F, Ali A, Kircher MF, Pal S. DNA Nanostructures and DNA-Functionalized Nanoparticles for Cancer Theranostics. ADVANCED SCIENCE (WEINHEIM, BADEN-WURTTEMBERG, GERMANY) 2020; 7:2001669. [PMID: 33304747 PMCID: PMC7709992 DOI: 10.1002/advs.202001669] [Citation(s) in RCA: 30] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/06/2020] [Revised: 08/27/2020] [Indexed: 05/12/2023]
Abstract
In the last two decades, DNA has attracted significant attention toward the development of materials at the nanoscale for emerging applications due to the unparalleled versatility and programmability of DNA building blocks. DNA-based artificial nanomaterials can be broadly classified into two categories: DNA nanostructures (DNA-NSs) and DNA-functionalized nanoparticles (DNA-NPs). More importantly, their use in nanotheranostics, a field that combines diagnostics with therapy via drug or gene delivery in an all-in-one platform, has been applied extensively in recent years to provide personalized cancer treatments. Conveniently, the ease of attachment of both imaging and therapeutic moieties to DNA-NSs or DNA-NPs enables high biostability, biocompatibility, and drug loading capabilities, and as a consequence, has markedly catalyzed the rapid growth of this field. This review aims to provide an overview of the recent progress of DNA-NSs and DNA-NPs as theranostic agents, the use of DNA-NSs and DNA-NPs as gene and drug delivery platforms, and a perspective on their clinical translation in the realm of oncology.
Collapse
Affiliation(s)
- Fay Nicolson
- Department of ImagingDana‐Farber Cancer Institute & Harvard Medical SchoolBostonMA02215USA
- Center for Molecular Imaging and NanotechnologyMemorial Sloan Kettering Cancer CenterNew YorkNY10065USA
| | - Akbar Ali
- Department of ChemistryIndian Institute of Technology‐ BhilaiRaipurChhattisgarh492015India
| | - Moritz F. Kircher
- Department of ImagingDana‐Farber Cancer Institute & Harvard Medical SchoolBostonMA02215USA
- Center for Molecular Imaging and NanotechnologyMemorial Sloan Kettering Cancer CenterNew YorkNY10065USA
- Department of RadiologyBrigham and Women's Hospital & Harvard Medical SchoolBostonMA02215USA
| | - Suchetan Pal
- Department of ChemistryIndian Institute of Technology‐ BhilaiRaipurChhattisgarh492015India
| |
Collapse
|
20
|
Spectral photon-counting CT imaging of colorectal peritoneal metastases: initial experience in rats. Sci Rep 2020; 10:13394. [PMID: 32770125 PMCID: PMC7414131 DOI: 10.1038/s41598-020-70282-w] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2020] [Accepted: 07/23/2020] [Indexed: 12/16/2022] Open
Abstract
Computed tomography imaging plays a major role in the preoperative assessment of tumor burden by providing an accurate mapping of the distribution of peritoneal metastases (PM). Spectral Photon Counting Computed Tomography (SPCCT) is an innovative imaging modality that could overcome the current limitations of conventional CT, offering not only better spatial resolution but also better contrast resolution by allowing the discrimination of multiple contrast agents. Based on this capability, we tested the feasibility of SPCCT in the detection of PM at different time of tumor growth in 16 rats inoculated with CC531 cells using dual-contrast injection protocols in two compartments (i.e. intravenous iodine and intraperitoneal gadolinium or the reverse protocol), compared to surgery. For all peritoneal regions and for both protocols, sensitivity was 69%, specificity was 100% and accuracy was 80%, and the correlation with surgical exploration was strong (p = 0.97; p = 0.0001). No significant difference was found in terms of diagnostic performance, quality of peritoneal opacification or diagnostic quality between the 2 injection protocols. We also showed poor vascularization of peritoneal metastases by measuring low concentrations of contrast agent in the largest lesions using SPCCT, which was confirmed by immunohistochemical analyses. In conclusion, SPCCT using dual-contrast agent injection protocols in 2 compartments is a promising imaging modality to assess the extent of PM in a rat model.
Collapse
|